{
    "Trade/Device Name(s)": [
        "ImmuLisa\u2122 Enhanced Centromere Antibody ELISA",
        "Centromere Antibody ELISA"
    ],
    "Submitter Information": "IMMCO Diagnostics Inc.",
    "510(k) Number": "K151559",
    "Predicate Device Reference 510(k) Number(s)": [
        "INOVA QUANTA Lite\u2122 Centromere ELISA"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LJM"
    ],
    "Summary Letter Date": "February 5, 2016",
    "Summary Letter Received Date": "February 5, 2016",
    "Submission Date": "March 6, 2016",
    "Regulation Number(s)": [
        "21CFR866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Anti-centromere IgG antibodies",
        "CENP-A",
        "CENP-B"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunoassay (ELISA)",
        "Solid phase immunoassay",
        "Microwell assay",
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Qualitative detection",
        "Semi-quantitative detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ImmuLisa Enhanced Centromere Antibody ELISA for detection of anti-centromere IgG antibodies in human serum for autoimmune disease diagnosis",
    "Indications for Use Summary": "Qualitative or semi-quantitative detection of anti-centromere IgG antibodies in human serum as an aid in diagnosis of limited cutaneous systemic sclerosis / CREST syndrome, used in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}